18.07

19.22% -4.30

After Hours: 17.60 -0.47 -2.60%

Crescent Biopharma Inc (CBIO)

Overview News Price History Discussions Forecast Stock Split Dividend History

Crescent Biopharma Inc stock is traded at $18.07, with a volume of 981.73K. It is down -19.22% in the last 24 hours and down -6.47% over the past month. Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Previous Close:

$22.37

Open:

$20.45

24h Volume:

981.73K

Relative Volume:

4.05

Market Cap:

$550.45M

Revenue:

$11.88M

Net Income/Loss:

$-162.08M

P/E Ratio:

-1.4475

EPS:

-12.484

Net Cash Flow:

$-156.43M

1W Performance:

-27.14%

1M Performance:

-6.47%

6M Performance:

+41.73%

1Y Performance:

+3,434%

1-Day Range:

$14.91

$21.43

1-Week Range:

$14.91

$26.53

52-Week Range:

$8.72

$27.41

Crescent Biopharma Inc Stock (CBIO) Company Profile

Name

Crescent Biopharma Inc

Sector

Healthcare (1113)

Industry

Biotechnology (622)

Phone

617-430-5595

Address

300 FIFTH AVENUE, WALTHAM, CA

Employee

Twitter

@catalystbio

Next Earnings Date

2026-05-13

Latest SEC Filings

CBIO's Discussions on Twitter

Compare CBIO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CBIO Crescent Biopharma Inc	18.07	550.45M	11.88M	-162.08M	-156.43M	-12.48
VRTX Vertex Pharmaceuticals Inc	423.92	107.83B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.42	73.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	783.50	48.72B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	39.51B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	32.66B	5.36B	287.73M	924.18M	2.5229

Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Initiated	Piper Sandler	Overweight
Jan-21-26	Initiated	Guggenheim	Buy
Aug-25-25	Initiated	Jefferies	Buy
Aug-11-25	Initiated	H.C. Wainwright	Buy
Jul-14-25	Initiated	Wedbush	Outperform
Jun-25-25	Initiated	Stifel	Buy
Mar-21-25	Initiated	Cantor Fitzgerald	Overweight
Mar-11-25	Initiated	Noble Capital Markets	Outperform
Jul-26-24	Downgrade	TD Cowen	Buy → Hold
Dec-22-23	Initiated	CapitalOne	Overweight
Nov-12-21	Upgrade	Jefferies	Hold → Buy
Apr-29-21	Resumed	Stephens	Overweight
Feb-10-21	Initiated	Piper Sandler	Overweight
May-21-20	Initiated	Raymond James	Outperform
Nov-14-19	Initiated	ROTH Capital	Buy
Aug-05-19	Downgrade	Jefferies	Buy → Hold
Aug-05-19	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-05-19	Downgrade	SunTrust	Buy → Hold
Apr-12-19	Initiated	Piper Jaffray	Overweight
Jan-04-19	Initiated	Oppenheimer	Outperform
Dec-18-18	Initiated	H.C. Wainwright	Buy
Feb-12-18	Reiterated	B. Riley FBR, Inc.	Buy
Feb-09-18	Reiterated	Chardan Capital Markets	Buy
Dec-08-17	Initiated	B. Riley FBR, Inc.	Buy
Jun-12-17	Initiated	Chardan Capital Markets	Buy
Jun-06-17	Initiated	Ladenburg Thalmann	Buy
Jul-26-16	Initiated	SunTrust	Buy
Jun-30-16	Initiated	Rodman & Renshaw	Buy
Mar-17-15	Reiterated	Stifel	Buy

View All

Crescent Biopharma Inc Stock (CBIO) Latest News

May 01, 2026

Crude Oil Down 3%; Chevron Posts Mixed Q1 Results - Benzinga

May 01, 2026

Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Cuts Target Price to $30 - Moomoo

May 01, 2026

Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue - Benzinga

May 01, 2026

Crescent Biopharma Down Over 16%, On Pace for Largest Percent Decrease Since July 2024 -- Data Talk - Moomoo

May 01, 2026

Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX), Cytokinetics (CYTK) and Crescent Biopharma (CBIO) - The Globe and Mail

May 01, 2026

CBIO Price Today: Crescent Biopharma, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange

May 01, 2026

Apr 29, 2026

Crescent Biopharma: Q1 Earnings Snapshot - Barchart

Apr 29, 2026

Crescent Biopharma (CBIO) registers 19.58M ordinary shares for resale - Stock Titan

Apr 29, 2026

Crescent Biopharma (NASDAQ: CBIO) posts Q1 2026 loss and oncology pipeline update - Stock Titan

Apr 29, 2026

Crescent lines up 2027 cancer trial readouts with cash into 2028 - Stock Titan

Apr 29, 2026

Crescent Biopharma (CBIO) Q1 2026 results show $23.3M loss and $189M cash - Stock Titan

Apr 29, 2026

Crescent Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

Apr 29, 2026

Apr 28, 2026

MSN Money - MSN

Apr 28, 2026